PLAY PODCASTS
BTK Inhibitors in CLL and Lymphomas: Overview and  Current Indications
Episode 75

BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications

Listen to Beth Faiman, PhD, MSN, APRN-BC, AOCN, provide a nursing-focused overview of BTK inhibitors in the treatment of CLL and other B-cell malignancies including the most recent evidence reported from major oncology conferences.

Decera Clinical Education Oncology Podcast

July 23, 202113m 46s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include:

  • Rationale for inhibiting BTK
  • MOA of BTK inhibitors
  • Approved BTK inhibitors
  • Recent clinical trial findings

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Presenter: 

Beth Faiman, PhD, MSN, APRN-BC, AOCN
Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

bgb-3111-206aspenmantle cell lymphomab-cell receptoribrutinibwaldenström macroglobulinemiazanubrutiniblymphomascllbtkace-ly-004acalabrutinibelevate-rralpinebtkielevate-tn